GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound 13 [WO2021188450]
Compound class:
Synthetic organic
Comment: The chemical structure for this compound was obtained from WHO INN proposed list 134 (Feb 2026), in which it is described as a NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome inhibitor with potential as a non-steroidal anti-inflammatory agent. It is one of the structures claimed in Zomagen Biosciences' (now part of Eli Lilly via a previous Ventyx Biosciences merger) patent WO2021188450 [1]. Evidence suggests that abdenoflast is likely the INN for the peripherally restricted NLRP3 inhibitor VTX2735 [2].
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Mohan R, Nuss J, Harris J, Yuan S. (2021)
Nlrp3 modulators. Patent number: WO2021188450A1. Assignee: Zomagen Biosciences Ltd. Priority date: 15/03/2021. Publication date: 23/09/2021. |
|
2. Ventyx Biosciences.
VTX2735: Peripherally restricted NLRP3 inhibitor for systemic autoinflammatory diseases and conditions. Accessed on 02/03/2026. Modified on 02/03/2026. ventyxbio.com, https://ventyxbio.com/pipeline/#VTX2735 |